From a strategic standpoint, the Blockchain in Genomics market outlook appears highly attractive, driven by escalating data‑privacy regulations and the exponential growth of genomic datasets. The market’s revenue potential is amplified by a moderate to high competitive intensity, as a handful of well‑capitalized startups and established biotech firms vie to integrate immutable ledger technology with precision‑medicine platforms. Over the long term, we anticipate a compound annual growth rate exceeding 30% through 2035, underpinned by expanding cross‑border collaborations and reimbursement frameworks that reward secure data sharing. Innovation is vibrant, with breakthroughs in zero‑knowledge proofs, token‑based incentive models, and hybrid on‑chain/off‑chain architectures reshaping value chains. The demand–supply balance currently tilts toward demand, creating a modest shortage of skilled blockchain‑genomics engineers and interoperable standards. Key risk factors include regulatory heterogeneity across jurisdictions, potential scalability bottlenecks of public chains, and the uncertainty of monetization models for data marketplaces. Decision‑makers should therefore prioritize partnerships that secure compliance, invest in talent pipelines, and monitor standard‑setting bodies to mitigate these risks.